![The ideal combination partner for BiTE therapy](https://oncodaily.com/pub/uploads/2024/07/BiTE-e1721135679686-1280x960.png)
The ideal combination partner for BiTE therapy
Michael Wang, Professor in the Department of Lymphoma/Myeloma and the Department of Stem Cell Transplantation and Cellular Therapy at MD Anderson Cancer Center, shared a post on X about a recent paper titled “Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy” published in Haematologica Journal:
Authors: Mika Casey, Carol Lee, Sharon M. Hoyte, Rebecca L. Johnston, Wing Yu Kwok, Soi Cheng Law, Maher K. Gandhi, Simon J. Harrison, and Kyohei Nakamura. .
“Thorough study in Haematologica screens immunostimulatory cytokines to determine the ideal combination partner for BiTE therapy and reveals IL21’s ability to augment BiTE-mediated release of granzyme B and perforin, without increasing IFN-γ release.”
Source: Michael Wang/X The ideal combination